[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 2061 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S. 2061 To require the Interagency Working Group on Toxic Exposure to conduct research on the diagnosis and treatment of health conditions of descendants of individuals exposed to toxic substances while serving as members of the Armed Forces, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES June 12, 2025 Mr. Blumenthal (for himself and Mrs. Murray) introduced the following bill; which was read twice and referred to the Committee on Veterans' Affairs _______________________________________________________________________ A BILL To require the Interagency Working Group on Toxic Exposure to conduct research on the diagnosis and treatment of health conditions of descendants of individuals exposed to toxic substances while serving as members of the Armed Forces, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Molly R. Loomis Research for Descendants of Toxic Exposed Veterans Act of 2025''. SEC. 2. RESEARCH ON DIAGNOSIS AND TREATMENT OF HEALTH CONDITIONS OF DESCENDANTS OF INDIVIDUALS EXPOSED TO TOXIC SUBSTANCES WHILE SERVING IN ARMED FORCES. (a) In General.--Subsection (b) of section 501 of the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 (Public Law 117-168) is amended by adding at the end the following new paragraph: ``(3) Establish Federal interagency task forces to conduct collaborative research activities.''. (b) Reporting.--Subsection (c) of such section is amended by striking paragraphs (2) and (3) and inserting the following: ``(2) Not later than one year after the date of the enactment of the Molly R. Loomis Research for Descendants of Toxic Exposed Veterans Act of 2025-- ``(A) a report containing a description of the collaborative research activities identified by the Working Group under subsection (b); ``(B) the findings of the members of the Working Group with respect to the collaborative research activities described in subparagraph (A); and ``(C) such recommendations as the Working Group may have for legislative or administrative action to improve collaborative research activities among the members of the Working Group. ``(3) Not less frequently than annually during the five- year period covered by the strategic plan developed under subsection (b)-- ``(A) a summary of the collaborative research activities carried out by the members of the Working Group and the findings of the members with respect to such research activities; ``(B) a progress report on implementation of the strategic plan developed by the Working Group under subsection (b); and ``(C) such recommendations as the Working Group may have for legislative or administrative action to improve collaborative research activities among members of the Working Group.''. (c) Research Requirements.--Such section is amended-- (1) by redesignating subsections (c) through (e) as subsections (d) through (f), respectively; (2) in subsection (e), as redesignated by paragraph (1), by striking ``under subsection (c)'' and inserting ``under subsection (d)''; and (3) by inserting after subsection (b) the following new subsection (c): ``(c) Requirements Relating to Certain Research on Impacts to Descendants.--Not later than 180 days after the date of the enactment of the Molly R. Loomis Research for Descendants of Toxic Exposed Veterans Act of 2025, the Working Group and the Agency for Toxic Substances and Disease Registry shall-- ``(1) establish an interagency task force to conduct research on the diagnosis and treatment of health conditions of descendants of toxic-exposed veteran (as defined in section 101 of title 38, United States Code); and ``(2) maintain a publicly available website with information on the activities and findings of the Agency under paragraph (1), including a review of all relevant data to determine the strength of evidence for a positive association between a health condition researched and a toxic exposure risk activity (as defined in section 1710(e)(4) of title 38, United States Code) based on the categories set forth under section 1173(c)(2) of title 38, United States Code.''. <all>